Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma Company is a partnership organized under the laws of Delaware, composed of E.R. Squibb & Sons, L.L.C., a Delaware limited liability company, and Bristol-Myers Squibb Pharma Holding Company, L.L.C., a Delaware limited liability company. ()
16 - Paper, cardboard and goods made from these materials
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Printed matter, namely, promotional and informational materials in the nature of brochures, booklets, pamphlets, newsletters, and stationery relating to pharmaceuticals for the treatment and prevention of cardiovascular diseases Health care services, namely, providing information to physicians, health care professionals and patients in the field of health care and pharmaceuticals for the treatment and prevention of cardiovascular diseases; providing a website featuring educational information in the field of health care and pharmaceuticals for the treatment and prevention of cardiovascular diseases
Methods and compositions are provided useful in the diagnosis, treatment and management of cancers wherein cancer cells express certain polynucleotides and/or polypeptides that are differentially expressed in colon cancer subtypes that are sensitive to therapy with abl kinase inhibitors and src kinase inhibitors. In particular, PTK-7, PLK-2 and PLK-3 could be identified as markers for determining the responsiveness of cancer to dasatinib.
Novel β1 adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also provided. The novel compounds may exhibit high affinity and selectivity, minimal metabolism, minimal non-specific binding and have a favorable log P value (< 0). In some instances, β1-AR selective ligands are conjugated to an imaging moiety in such a way that it does not impact the antagonist affinity and their use. In other instances, the conjugation may be directly to the antagonist at several sites that will not impact affinity. In further instances, the conjugation may be by means of a linking group, which can be used to alter the pharmacokinetics and clearance of the complex.
C07C 255/54 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
C07C 275/34 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
C07C 275/42 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 231/20 - One oxygen atom attached in position 3 or 5
C07D 295/215 - Radicals derived from nitrogen analogues of carbonic acid
C07B 59/00 - Introduction of isotopes of elements into organic compounds
The present invention is directed, in part, to compounds and methods for diagnostic imaging, comprising administering to a patient a contrast agent which has an overall negative charge.
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.
The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions, for example BMS-354825/dasatinib, useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins.
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
8.
METHODS OF MAKING RADIOLABELED TRACERS AND PRECURSORS THEREOF
The present disclosure relates to a solid-phase process for the production of radiolabeled tracers, in particular for the production of 18F-labeled compounds which may be used as Positron Emission Tomography (PET) radiolabeled tracers. The disclosure also relates to radiopharmaceutical kits comprising precursors to the radiolabeled tracers, which can be converted to the radiolabeled tracers using the processes described herein.
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
C07D 239/82 - Oxygen atoms with an aryl radical attached in position 4
C07D 309/38 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
The present disclosure is directed to diagnostic agents. More specifically, the disclosure is directed to compounds, diagnostic agents, compositions, and kits for detecting and/or imaging and/or monitoring a pathological disorder associated with coronary plaque, carotid plaque, aortic plaque, plaque of the arterial vessel, aneurism, vasculitis, and other diseases of the arterial wall. In addition, the disclosure is directed to methods of detecting and/or imaging and/or monitoring changes in the arterial wall, including expansive and constrictive remodeling, total vessel wall area, internal lumen size, and exterior artery perimeter.
Temple University - Of The Commonwealth System of Higher Education (USA)
Bristol-Myers Squibb Pharma Company (USA)
Inventor
Colman, Robert W.
Mousa, Shaker A.
Abstract
Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis.
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
Goods & Services
(1) Booklet and health journal (calendar). (1) Enrollment in a patient support program which involves receiving periodic mailings with additional information about their anticoagulant therapy.
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
Goods & Services
(1) Booklet and health journal (calendar). (1) Enrollment in a patient support program which involves receiving periodic mailings with additional information about their anticoagulant therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of cardiovascular diseases, central nervous system diseases, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases and for diagnostic imaging.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of cardiovascular diseases, central nervous system diseases, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases and for diagnostic imaging.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of cardiovascular diseases, central nervous system diseases, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases and for diagnostic imaging.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, for the treatment of cardiovascular diseases, central nervous system diseases, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases and for diagnostic imaging.